Assetmark Inc. Has $2.01 Million Stock Position in Genmab A/S (NASDAQ:GMAB)

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of the company’s stock after purchasing an additional 11,519 shares during the quarter. Assetmark Inc.’s holdings in Genmab A/S were worth $2,014,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. DDD Partners LLC acquired a new stake in shares of Genmab A/S in the second quarter worth $8,860,000. Capital International Investors lifted its stake in Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after acquiring an additional 145,689 shares during the period. Renaissance Technologies LLC grew its stake in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Genmab A/S in the second quarter worth approximately $1,354,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GMAB. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Morgan Stanley reissued an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial dropped their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Price Performance

NASDAQ GMAB opened at $21.66 on Thursday. Genmab A/S has a fifty-two week low of $21.59 and a fifty-two week high of $32.89. The stock’s 50-day moving average is $24.20 and its two-hundred day moving average is $26.31. The firm has a market cap of $14.33 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 0.70 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the business posted $0.47 earnings per share. On average, equities analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.